Mirum Pharmaceuticals Announces FDA Acceptance of New Drug Application and Priority Review for Maralixibat in Alagille Syndrome

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mar. 29, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) announced today that its New Drug Application (NDA) for maralixibat, an oral apical sodium dependent bile acid transporter (ASBT) inhibitor...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news